Bifogade filer
PDF
Beskrivning
| Land | Finland |
|---|---|
| Lista | Spotlight |
| Sektor | Handel & varor |
| Industri | Detaljhandel |
Eevia Health Plc ("Eevia" or "The Company") has initiated a MEUR 2.6 sales transaction with Baccas Salus, a startup, for equipment, products, and berry extract manufacturing IP, yielding Eevia a MEUR 1.5 gain. The deal awaits approvals and payment from Baccas Salus Oy.
For immediate release
Seinäjoki, Finland 13.02.2025
Eevia has agreed to sell equipment, machines, and products to Finnish start-up Baccas Salus for MEUR 2.6. The book value of these assets was c. MEUR 1.1 as of 31.12.24, generating a MEUR 1.5M gain on sale of fixed assets for Eevia. The sale is subject to creditor and board approvals, as well as payments, which include cash and a seller's credit convertible into Baccas Salus shares.
Ownership and possession remain with Eevia until the cash payment is made and all approvals are secured. Baccas Salus must also complete financing transactions, and failure to meet these conditions could nullify the deal. Upon a fully consumed transaction, Eevia will rent the equipment and use for manufacture of berry extracts at its facility until the green field is operational and ready to receive the assets and overtake the berry extract production.
Baccas Salus plans to build a new, automated, energy- and material-efficient berry manufacturing facility near key harvest areas, potentially also innovating aspects of procurement and berry harvest. Eevia will continue selling products from this facility, maintaining close cooperation. The transaction streamlines Eevia's operations, improving its balance sheet and reducing costs, CAPEX, and depreciation.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
This disclosure contains information that EEVIA HEALTH PLC must make public according to the EU Market Abuse Regulation (EU nr 596/2014). The information was originally submitted for publication through the contact person's agency on February 13, 2025, at 12:30 EST.
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.
Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.